Patents by Inventor Andrew Dillin

Andrew Dillin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180216113
    Abstract: The present disclosure provides methods of reducing protein misfolding and/or aggregation in a cell. The present disclosure provides methods of treating diseases and disorders associated with protein misfolding and/or aggregation.
    Type: Application
    Filed: August 18, 2016
    Publication date: August 2, 2018
    Inventors: Andrew Dillin, Hyun-Eui Kim
  • Publication number: 20170037117
    Abstract: The disclosure features compositions and methods for treating a metabolic disorder, including diabetes, conditions associated with inhibition of insulin secretion, or for increasing longevity. In some embodiments, the methods comprise administering an anti-CGRP antagonist antibody.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Applicants: Salk Institute for Biological Studies, The Regents of the University of California, Labrys Biologics, Inc.
    Inventors: Andrew Dillin, Celine Riera, Corey Goodman
  • Patent number: 8653080
    Abstract: The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: February 18, 2014
    Assignee: Salk Institute for Biological Studies
    Inventors: Andrew Dillin, Thomas J. Baiga, Erik Kapernick, Joseph P. Noel
  • Publication number: 20130065834
    Abstract: Methods of modulating proteasome activity, increasing life span and neurogenesis are provided herein.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 14, 2013
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: David Vilchez, Andrew Dillin
  • Publication number: 20120189638
    Abstract: The invention is directed to a method of treating a patient suffering from Alzheimer's disease comprising administering to said patient an agent that reduces the activity of the IGF-1 signaling pathway.
    Type: Application
    Filed: June 23, 2011
    Publication date: July 26, 2012
    Inventors: Andrew Dillin, Ehud Cohen
  • Publication number: 20120172413
    Abstract: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to CRTC modulation. In certain embodiments, the invention provides compositions and methods for enhancing longevity in an organism by inhibiting CRTC activity, such as, for example, inhibiting CRTC expression or cellular localization in the organism.
    Type: Application
    Filed: June 28, 2010
    Publication date: July 5, 2012
    Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Andrew Dillin, William Mair, Ianessa Morantte, Reuben Shaw
  • Publication number: 20120148565
    Abstract: Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevity by assaying wwp-1 ubiquitination pathway parameters are provided, as are related systems. In addition, methods of using wwp-1 and/or ubc-18 to modulate longevity or delay onset of age-related diseases are described.
    Type: Application
    Filed: September 23, 2011
    Publication date: June 14, 2012
    Applicant: The Salk Institute for Biological Studies
    Inventors: Andrea C. CARRANO, Andrew DILLIN, Tony HUNTER
  • Publication number: 20120122957
    Abstract: The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to modulation of mitochondrial function. In certain embodiments, the invention provides methods and related compositions for the enhancement of longevity in an animal, comprising inhibition of one or more electron transport chain components, such as cco-1 and homologs thereof, in a tissue-specific manner in the animal.
    Type: Application
    Filed: April 19, 2010
    Publication date: May 17, 2012
    Applicant: The Salk Institute for Biological Studies
    Inventors: Andrews Dillin, Jennie Durieux
  • Patent number: 8058502
    Abstract: Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevity by assaying wwp-1 ubiquitination pathway parameters are provided, as are related systems. In addition, methods of using wwp-1 and/or ubc-18 to modulate longevity or delay onset of age-related diseases are described.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: November 15, 2011
    Assignee: The Salk Institute for Biological Studies
    Inventors: Andrea C. Carrano, Andrew Dillin, Tony Hunter
  • Patent number: 7833727
    Abstract: The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response pathway and the insulin/IGF-1 pathway and longevity, Smek1 represents an essential target for modulation of life span and the stress response. Methods of increasing life span and stress tolerance by modulation of Smek activity are disclosed, as are screening methods for identifying compounds that modulate Smek activity. In addition, recombinant animals expressing the Smek gene that have a longer life span and enhanced stress tolerance, and methods of using the Smek gene to modulate both longevity and stress tolerance, are described.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 16, 2010
    Assignee: The Salk Institute for Biological Studies
    Inventors: Hui Ma, Tony Hunter, Suzanne C. Wolff, Andrew Dillin
  • Publication number: 20100263062
    Abstract: The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.
    Type: Application
    Filed: January 14, 2010
    Publication date: October 14, 2010
    Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Andrew Dillin, Thomas J. Baiga, Erik Kapernick, Joseph P. Noel
  • Patent number: 7794957
    Abstract: The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for activators of the heat shock factor 1 (HSF-1) protein, which increases lifespan when overexpressed in an organism.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: September 14, 2010
    Assignee: Regents of the University of California
    Inventors: Cynthia Kenyon, Javier Apfeld, Andrew Dillin, Delia Garigan, Ao-Lin A. Hsu, Josh Lehrer-Graiwer, Coleen Murphy
  • Publication number: 20090208960
    Abstract: Methods for identifying a cellular modulator of a biological disaggregation activity or a biological aggregation activity of an animal are provided. Methods for identifying a compound which modulates biological disaggregation activity or a biological aggregation activity in a biological sample are provided.
    Type: Application
    Filed: February 10, 2009
    Publication date: August 20, 2009
    Inventors: Jeffrery W. Kelly, Jan Gerd Maximilian Bieschke, Andrew Dillin, Ehud Cohen
  • Publication number: 20090092551
    Abstract: The roles of the pha-4 and daf-16 genes in diet-restricted induced longevity are described and characterized. Pha-4 acts, e.g., in the absence of daf-16, to increase lifespan, e.g., in nematodes. Given the role that pha-4 and daf-16 play in the mediation of longevity, they represent targets for modulation of life span. Methods of increasing life span and delaying age onset diseases by modulation of pha-4 activity are disclosed, as are screening methods for identifying compounds that modulate pha-4 and/or daf-16 activity. In addition, recombinant animals expressing the pha-4 gene and not the daf-16 gene, and methods of using the pha-4 and/or daf-16 genes to modulate longevity and age-onset diseases are described.
    Type: Application
    Filed: July 17, 2008
    Publication date: April 9, 2009
    Inventors: Andrew Dillin, Hugo Aguilaniu, Siler Panowski, Suzanne C. Wolff
  • Publication number: 20090083868
    Abstract: Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevity by assaying wwp-1 ubiquitination pathway parameters are provided, as are related systems. In addition, methods of using wwp-1 and/or ubc-18 to modulate longevity or delay onset of age-related diseases are described.
    Type: Application
    Filed: August 15, 2008
    Publication date: March 26, 2009
    Inventors: Andrea C. Carrano, Andrew Dillin, Tony Hunter
  • Publication number: 20080249012
    Abstract: The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response pathway and the insulin/IGF-1 pathway and longevity, Smek1 represents an essential target for modulation of life span and the stress response. Methods of increasing life span and stress tolerance by modulation of Smek activity are disclosed, as are screening methods for identifying compounds that modulate Smek activity. In addition, recombinant animals expressing the Smek gene that have a longer life span and enhanced stress tolerance, and methods of using the Smek gene to modulate both longevity and stress tolerance, are described.
    Type: Application
    Filed: October 29, 2007
    Publication date: October 9, 2008
    Inventors: Hui MA, Tony Hunter, Suzanne C. Wolff, Andrew Dillin
  • Patent number: 7288385
    Abstract: The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response pathway and the insulin/IGF-1 pathway and longevity, Smek1 represents an essential target for modulation of life span and the stress response. Methods of increasing life span and stress tolerance by modulation of Smek activity are disclosed, as are screening methods for identifying compounds that modulate Smek activity. In addition, recombinant animals expressing the Smek gene that have a longer life span and enhanced stress tolerance, and methods of using the Smek genet to modulate both longevity and stress tolerance, are described.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: October 30, 2007
    Assignee: The Salk Institute for Biological Studies
    Inventors: Hui Ma, Tony Hunter, Suzanne C. Wolff, Andrew Dillin
  • Publication number: 20060228707
    Abstract: The present invention relates to regulation of lifespan in eukaryotes. More particularly, one aspect of the present invention is the identification of genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, antisense nucleic acids, and ribozymes, that regulate, e.g., enhance, adult lifespan via modulation of aging associated proteins; as well as to the use of expression profiles, promoters, reporter genes, markers, and compositions in diagnosis and therapy related to lifespan extension, life expectancy, and aging. The present invention also relates to gene therapy involving lifespan associated genes.
    Type: Application
    Filed: August 11, 2003
    Publication date: October 12, 2006
    Applicant: The Regents of the University of California
    Inventors: Cynthia Kenyon, Jennifer Berman, Andrew Dillin, Malene Hansen, Ao-lin Hsu, Coleen Murphy
  • Publication number: 20060162002
    Abstract: The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. For example, the present invention is directed to genes encoding components of the mitochondrial respiratory chain and genes encoding glycolysis enzymes, which are involved in lifespan regulation, and genes and gene products in pathways controlled by such genes.
    Type: Application
    Filed: November 18, 2005
    Publication date: July 20, 2006
    Applicant: The Regents of the University of California
    Inventors: Cynthia Kenyon, Javier Apfeld, Andrew Dillin, Delia Garigan, Ao-Lin Hsu, Josh Lehrer-Graiwer, Coleen Murphy
  • Publication number: 20060019314
    Abstract: The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response pathway and the insulin/IGF-1 pathway and longevity, Smek1 represents an essential target for modulation of life span and the stress response. Methods of increasing life span and stress tolerance by modulation of Smek activity are disclosed, as are screening methods for identifying compounds that modulate Smek activity. In addition, recombinant animals expressing the Smek gene that have a longer life span and enhanced stress tolerance, and methods of using the Smek genet to modulate both longevity and stress tolerance, are described.
    Type: Application
    Filed: June 24, 2005
    Publication date: January 26, 2006
    Applicant: The Salk Institute for Biological Studies
    Inventors: Hui Ma, Tony Hunter, Suzanne Wolff, Andrew Dillin